A new algorithm in patients with elevated and/or rising prostate-specific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies

International Urology and Nephrology

Volumn 42, Issue 1, 2010, Pages 29-38

  Van Renterghem, Koenraad ^a   Van Koeveringe, Gommert ^b   Achten, Ruth ^a   Van Kerrebroeck, Philip ^b  

^a VIRGA JESSE HOSPITAL   (Belgium)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Benign prostatic hyperplasia (BPH); Bladder outlet obstruction (BOO); Elevated prostate specific antigen (PSA); Prostate cancer; Transurethral resection of the prostate (TURP)

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACUTE DISEASE; ALGORITHM; BLADDER NECK STENOSIS; COMORBIDITY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIGITAL RECTAL EXAMINATION; FEVER; HEMATURIA; HEMOSPERMIA; HISTOLOGY; HUMAN; LOWER URINARY TRACT SYMPTOM; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL RESECTION; URINE RETENTION; URODYNAMICS;

ALGORITHMS; BIOPSY; HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATISM; SEVERITY OF ILLNESS INDEX;

EID: 77950917904     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-009-9596-z     Document Type: Review

References (93)

1. RS Kirby 1992 The clinical assessment of benign prostatic hyperplasia Cancer 70 284 290 10.1002/1097-0142(19920701)70:1+<284::AID- CNCR2820701316>3.0.CO;2-# 10.1002/1097-0142(19920701)70:1+<284::AID- CNCR2820701316>3.0.CO;2-# 1:STN:280:DyaK383ovVygtg%3D%3D 1376198
2. TA Stamey N Yang AR Hay JE McNeal FS Freiha E Redwine 1987 Prostate specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 317 909 916 1:STN:280:DyaL2szhsFakug%3D%3D 2442609 (Pubitemid 17147932)
3. D Griffiths K Höfner R van Mastrigt HJ Rollema A Spangberg D Gleason 1997 Standardization of terminology of lower urinary tract function: pressure-flow studies of voiding, urethral resistance, and urethral obstruction Neurourol Urodyn 16 1 18 10.1002/(SICI)1520-6777(1997)16:1<1::AID-NAU1>3. 0.CO;2-I 10.1002/(SICI)1520-6777(1997)16:1<1::AID-NAU1>3.0.CO;2-I 1:STN:280:DyaK2s7ntlyrtQ%3D%3D 9021786 (Pubitemid 27053287)
4. K van Renterghem G Van Koeveringe P Van Kerrebroeck 2007 Rising PSA in patients with minor LUTS without evidence of prostatic carcinoma: a missing link? Int Urol Nephrol 39 1107 1113 10.1007/s11255-007-9209-7 10.1007/s11255-007-9209-7 17602307 (Pubitemid 350193602)
5. P Laguna G Alivizatos 2000 Prostate specific antigen and benign prostatic hyperplasia Curr Opin Urol 10 3 8 10.1097/00042307-200001000-00002 10.1097/00042307-200001000-00002 1:STN:280:DC%2BD3c7hs1artA%3D%3D 10650506 (Pubitemid 30066285)
6. WJ Catalona PC Southwick KM Slawin AW Partin MK Brawer RC Flanigan, et al. 2000 Comparison of percent free PSA, PSA density, and age-specific PSA cut-offs for prostate cancer detection and staging Urology 56 255 260 10.1016/S0090-4295(00)00637-3 10.1016/S0090-4295(00)00637-3 1:STN:280: DC%2BD3czpsVarsA%3D%3D 10925089 (Pubitemid 30495578)
7. JG Borer J Sherman MC Solomon MW Plawker RJ Macchia 1998 Age specific prostate specific antigen reference ranges: population specific J Urol 159 444 448 10.1016/S0022-5347(01)63945-4 10.1016/S0022-5347(01)63945-4 1:STN:280:DyaK1czhtFGqtg%3D%3D 9649260 (Pubitemid 28049253)
8. MC Benson IS Whang CA Olsson DJ McMahon WH Cooner 1992 The use of prostate-specific antigen density to enhance the predictive value of intermediate levels of serum prostate-specific antigen J Urol 147 817 821 1:STN:280:DyaK387mslChsQ%3D%3D 1371555
9. D Connolly A Black LJ Murray G Napolitano A Gavin PF Keane 2007 Methods of calculating prostate-specific antigen velocity Eur Urol 52 1044 1051 10.1016/j.eururo.2006.12.017 10.1016/j.eururo.2006.12.017 17197071 (Pubitemid 47332018)
10. HB Carter JD Pearson JE Metter DW Chan R Andres JL Fozard W Rosner, et al. 1992 Longitudinal evaluation of prostate-specific antigen levels in men without prostate disease JAMA 267 2215 2220 10.1001/jama.267.16.2215 10.1001/jama.267.16.2215 1:STN:280:DyaK383htFOrtQ%3D%3D 1372942
11. S Loeb KA Roehl WJ Catalona RB Nadler 2007 Prostate specific antigen velocity threshold for predicting prostate cancer in young men J Urol 177 899 902 10.1016/j.juro.2006.10.028 10.1016/j.juro.2006.10.028 17296371 (Pubitemid 46223578)
12. AP Berger M Deibl A Strasak J Bektic AE Pelzer H Klocker, et al. 2007 Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer Urology 69 134 138 10.1016/j.urology.2006.09.018 10.1016/j.urology.2006.09.018 17270635 (Pubitemid 46161684)
13. W Catalona D Smith R Wolfert TJ Wang HG Rittenhouse TL Ratliff, et al. 1995 Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening JAMA 274 1214 1220 10.1001/jama.274.15.1214 10.1001/jama.274.15.1214 1:CAS:528:DyaK2MXpslWmsbo%3D 7563511
14. M Froehner OW Hakenberg R Koch U Schmidt A Meye MP Wirth 2006 Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer Urol Int 76 27 30 10.1159/000089731 10.1159/000089731 16401917 (Pubitemid 43087517)
15. HJ Linton LS Marks LS Millar CL Knott HG Rittenhouse SD Mikolajczyk 2003 Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease Clin Chem 49 253 259 10.1373/49.2.253 10.1373/49.2.253 1:CAS:528:DC%2BD3sXptVGitg%3D%3D 12560348 (Pubitemid 36143447)
16. MA Khan LJ Sokoll DW Chan LA Mangold P Mohr SD Mikolajczyk, et al. 2004 Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15% Urology 64 1160 1164 10.1016/j.urology.2004.06.033 10.1016/j.urology.2004.06.033 15596190 (Pubitemid 39647059)
17. KM Slawin S Shariat E Canto 2005 BPSA: a novel serum marker for benign prostatic hyperplasia Rev Urol 7 S8 S52 S56 16985891
18. C Stephan K Jung M Lein EP Diamandis 2007 PSA and other tissue kallikreins for prostate cancer detection Eur J Cancer 43 1918 1926 10.1016/j.ejca.2007.06.006 10.1016/j.ejca.2007.06.006 1:CAS:528: DC%2BD2sXpsFKntbc%3D 17689069 (Pubitemid 47287733)
19. LS Marks Y Fradet IL Deras A Blase J Mathis SM Aubin, et al. 2007 PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy Urology 69 532 535 10.1016/j.urology.2006.12.014 10.1016/j.urology.2006.12.014 17382159 (Pubitemid 46428401)
20. D Hessels JM Klein Gunnewiek I van Oort HF Karthaus GJ van Leenders B van Balken, et al. 2003 DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer Eur Urol 44 8 15 10.1016/S0302-2838(03)00201-X 10.1016/S0302-2838(03)00201-X 1:CAS:528:DC%2BD3sXmt1WntLo%3D 12814669 (Pubitemid 36741368)
21. MP van Gils D Hessels O van Hooij SA Jannink WP Peelen SL Hanssen, et al. 2007 The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance Clin Cancer Res 13 939 943 10.1158/1078-0432.CCR-06-2679 10.1158/1078-0432.CCR-06-2679 17289888 (Pubitemid 46340370)
22. A Haese A de la Taille H van Poppel M Marberger A Stenzl PF Mulders, et al. 2008 Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy Eur Urol 54 1081 1088 10.1016/j.eururo.2008.06.071 10.1016/j.eururo.2008.06.071 18602209
23. IL Deras SM Aubin A Blase JR Day S Koo AW Partin, et al. 2008 PCA3: a molecular urine assay for predicting prostate biopsy outcome J Urol 179 1587 1592 10.1016/j.juro.2007.11.038 10.1016/j.juro.2007.11.038 18295257
24. K Hodge J McNeal M Terris TA Stamey 1989 Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate J Urol 142 71 75 1:STN:280:DyaL1M3otVSksA%3D%3D 2659827 (Pubitemid 19184006)
25. A Eskew R Bare D McCullough 1997 Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate J Urol 157 199 203 10.1016/S0022-5347(01)65322-9 10.1016/S0022-5347(01)65322-9 1:STN:280:DyaK2s7jtVCrtQ%3D%3D 8976250 (Pubitemid 26414957)
26. JL Gore SF Shariat BJ Miles D Kadmon N Jiang TM Wheeler, et al. 2001 Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer J Urol 165 1554 1559 10.1016/S0022-5347(05) 66347-1 10.1016/S0022-5347(05)66347-1 1:STN:280:DC%2BD3M3ovVOitw%3D%3D 11342916 (Pubitemid 32410237)
27. P Arnold T Niemann R Bahnson 2001 Extended sector biopsy for detection of carcinoma of the prostate Urol Oncol 6 91 93 10.1016/S1078-1439(00)00111-3 10.1016/S1078-1439(00)00111-3 (Pubitemid 32409992)
28. GC Durkan N Sheikh P Johnson AJ Hildreth DR Green 2002 Improving prostate cancer detection with an extended-core transrectal ultrasonography-guided prostate biopsy protocol BJU Int 89 33 39 10.1046/j.1464-410X.2002.02555.x 10.1046/j.1464-410X.2002.02555.x 1:STN:280:DC%2BD387hsVOqug%3D%3D 11849157 (Pubitemid 34117761)
29. K Matsumoto S Egawa T Satoh H Kuruma N Yanagisawa S Baba 2006 Computer simulated additional deep apical biopsy enhances cancer detection in palpably benign prostate gland Int J Urol 13 1290 1295 10.1111/j.1442-2042.2006.01557.x 10.1111/j.1442-2042.2006.01557.x 17010007 (Pubitemid 44453695)
30. P Lui M Terris J McNeal TA Stamey 1995 Indications for ultrasound guided transition zone biopsies in the detection of prostate cancer J Urol 153 1000 1003 10.1016/S0022-5347(01)67621-3 10.1016/S0022-5347(01)67621-3 1:STN:280:DyaK2M7ls1Knsw%3D%3D 7853548
31. M Bazinet P Karakiewicz A Aprikian C Trudel S Aronson M Nachabé, et al. 1996 Value of systematic transition zone biopsies in the early detection of prostate cancer J Urol 155 605 606 10.1016/S0022-5347(01)66463-2 10.1016/S0022-5347(01)66463-2 1:STN:280:DyaK287jsVejtQ%3D%3D 8558670 (Pubitemid 26023553)
32. MK Terris TQ Pham MM Issa JN Kabalin 1997 Routine transition zone and seminal vesicle biopsies in all patients undergoing transrectal ultrasound guided prostate biopsies are not indicated J Urol 157 204 206 10.1016/S0022-5347(01)65325-4 10.1016/S0022-5347(01)65325-4 1:STN:280: DyaK2s7jtVCrug%3D%3D 8976251
33. N Fleshner W Fair 1997 Indications for transition zone biopsy in the detection of prostatic carcinoma J Urol 157 556 558 10.1016/S0022-5347(01)65200- 5 10.1016/S0022-5347(01)65200-5 1:STN:280:DyaK2s7kvFGntQ%3D%3D 8996355 (Pubitemid 27026837)
34. G Guichard S Larrré A Gallina A Lazar H Faucan S Chemama, et al. 2007 Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients Eur Urol 52 430 435 10.1016/j.eururo.2007.02.062 10.1016/j.eururo.2007.02.062 17412489 (Pubitemid 46963444)
35. V Scattoni A Zlotta R Montironi C Schulman P Rogatto F Montorsi 2007 Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature Eur Urol 52 1309 1322 10.1016/j.eururo.2007.08.006 10.1016/j.eururo.2007.08.006 17720304 (Pubitemid 47446019)
36. RA Ashley BA Inman JC Routh LA Mynderse MT Gettman ML Blute 2008 Reassessing the diagnostic yield of saturation biopsy of the prostate Eur Urol 53 976 983 10.1016/j.eururo.2007.10.049 10.1016/j.eururo.2007.10.049 17997028 (Pubitemid 351434501)
37. R Raaijmakers W Kirkels M Roobol MF Wildhagen FH Schrder 2002 Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program Urology 60 826 830 10.1016/S0090-4295(02)01958-1 10.1016/S0090-4295(02)01958-1 12429309 (Pubitemid 35300348)
38. B Djavan V Ravery A Zlotta P Dobronski M Dobrovits M Fakhari, et al. 2001 Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 166 1679 1683 10.1016/S0022-5347(05)65652-2 10.1016/S0022-5347(05)65652-2 1:STN:280:DC%2BD3MrjvFWgtw%3D%3D 11586201
39. B Djavan YK Fong V Ravery M Waldert C Wiunig YK Fong, et al. 2005 Are repeat biopsies required in men with PSA levels =4 ng/ml? A multiinstitutional prospective European study Eur Urol 47 38 44 10.1016/j.eururo.2004.07.024 10.1016/j.eururo.2004.07.024 15582247 (Pubitemid 39575716)
40. J Morote M Lopez G Encabo IM de Torres 2000 Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen Eur Urol 37 537 540 10.1159/000020190 10.1159/000020190 1:STN:280:DC%2BD3c3ivFKksg%3D%3D 10765091 (Pubitemid 30189821)
41. JC Nickel DI Young S Boag 1999 Asymptomatic inflammation and/or infection in benign prostatic hyperplasia BJU Int 84 976 981 10.1046/j.1464-410x.1999. 00352.x 10.1046/j.1464-410x.1999.00352.x 1:STN:280:DC%2BD3c%2FktVOgtg%3D%3D 10571623
42. SG Chang CS Kim SH Jeon YW Kim BY Choi 2006 Is chronic inflammatory change in the prostate the major cause of rising serum prostate-specific antigen in patients with clinical suspicion of prostate cancer? Int J Urol 13 122 126 10.1111/j.1442-2042.2006.01244.x 10.1111/j.1442-2042.2006.01244.x 16563135 (Pubitemid 43362966)
43. W Demark-Wahnefried MA Moyad 2007 Dietary intervention in the management of prostate cancer Curr Opin Urol 17 168 174 10.1097/MOU.0b013e3280eb10fc 10.1097/MOU.0b013e3280eb10fc 17414514 (Pubitemid 46597436)
44. A Jatoi P Burch D Hillman JM Vanyo S Dakhil D Nikcevich, et al. 2007 A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a phase II study from the North Central Cancer Treatment group Urology 69 289 294 10.1016/j.urology.2006.10.019 10.1016/j.urology.2006. 10.019 17320666 (Pubitemid 46274937)
45. VA Kirsh ST Mayne U Peters N Chatterjee MF Leitzmann LB Dixon, et al. 2006 A prospective study of lycopene and tomato product intake and risk of prostate cancer Cancer Epidemiol Biomarkers Prev 15 92 98 10.1158/1055-9965.EPI- 05-0563 10.1158/1055-9965.EPI-05-0563 1:CAS:528:DC%2BD28XmvVSmtw%3D%3D 16434593
46. JA Eastham E Riedel L Latkany M Fleisher A Schatzkin E Lanza, et al. 2003 Dietary manipulation, ethnicity, and serum PSA levels Urology 289 677 682 10.1016/S0090-4295(03)00576-4 10.1016/S0090-4295(03)00576-4 (Pubitemid 37205004)
47. ME Laniado JL Ockrim A Marronaro A Tubaro SS Carter 2004 Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms BJU Int 94 1283 1286 10.1111/j.1464-410X.2004. 05158.x 10.1111/j.1464-410X.2004.05158.x 15610106 (Pubitemid 40052094)
48. CG Roehrborn JD McConnell M Lieber S Kaplan J Geller GH Malek, et al. 1999 Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia Urology 53 473 480 10.1016/S0090-4295(98)00654-2 10.1016/S0090-4295(98)00654-2 1:STN:280:DyaK1M7psVSgsQ%3D%3D 10096369 (Pubitemid 29136187)
49. CG Roehrborn JD McConnell J Bonilla S Rosenblatt PB Hudson GH Malek, et al. 2000 Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia J Urol 163 13 20 10.1016/S0022-5347(05)67962-1 10.1016/S0022-5347(05)67962-1 1:STN:280: DC%2BD3c%2FmslOqsQ%3D%3D 10604304
50. CA Mochtar LALM Kiemeney MP Laguna MM van Riemsdijk GS Barnett FM Debruyne, et al. 2005 Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting Urology 65 2 300 305 10.1016/j.urology.2004.09.030 10.1016/j.urology.2004.09.030 1:STN:280:DC%2BD2M%2FotVSltg%3D%3D 15708042 (Pubitemid 40248017)
51. O Bratt 2006 The difficult case in prostate cancer diagnosis-when is a "diagnostic TURP" indicated Eur Urol 49 769 771 10.1016/j.eururo.2006. 01.010 10.1016/j.eururo.2006.01.010 16457943
52. P Puppo 2007 Repeated negative prostate biopsies with persistently elevated or rising PSA: a modern urologic dilemma Eur Urol 52 639 641 10.1016/j.eururo.2007.04.004 10.1016/j.eururo.2007.04.004 1:CAS:528: DC%2BD2sXhtVKgs7zM 17451871 (Pubitemid 47126170)
53. ES Rovner FJ Schanne SB Malkowicz AJ Wein 1997 Transurethral biopsy of the prostate for persistently elevated or increasing prostate specific antigen following multiple negative transrectal biopsies J Urol 158 138 142 10.1097/00005392-199707000-00042 10.1097/00005392-199707000-00042 1:STN:280:DyaK2szivFyrsw%3D%3D 9186340 (Pubitemid 27251610)
54. H Kitamura N Masumori Y Tanuma M Yanase N Itoh A Takahashi, et al. 2002 Does transurethral resection of the prostate facilitate detection of clinically significant prostate cancer that is missed with systematic sextant and transition zone biopsies? Int J Urol 9 95 99 10.1046/j.1442-2042.2002.00428.x 10.1046/j.1442-2042.2002.00428.x 12028299 (Pubitemid 34299177)
55. R Zigeuner L Schips K Lipsky M Auprich M Salfellner P Rehak, et al. 2003 Detection of prostate cancer by TURP or open surgery in patients with previously negative transrectal prostate biopsies Urology 62 883 887 10.1016/S0090- 4295(03)00663-0 10.1016/S0090-4295(03)00663-0 14624913 (Pubitemid 37421236)
56. C Özden G Inal Ö Asan S Yazici B Ozturk M Cetinkaya 2003 Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA Urol Int 71 150 153 10.1159/000071837 10.1159/000071837 12890951 (Pubitemid 36928784)
57. S Radhakrishnan TJ Dorkin N Sheikh DR Greene 2004 Role of transition zone sampling by TURP in patients with raised PSA and multiple negative transrectal ultrasound-guided prostatic biopsies Prostate Cancer Prostatic Dis 7 338 342 10.1038/sj.pcan.4500756 10.1038/sj.pcan.4500756 1:STN:280:DC%2BD2cnhvFWisg%3D%3D 15365579 (Pubitemid 41721793)
58. J Philip S Dutta Roy J Scally CS Foster P Javlé 2005 Importance of TURP in diagnosing prostate cancer in men with multiple negative biopsies Prostate 64 200 202 10.1002/pros.20239 10.1002/pros.20239 1:STN:280: DC%2BD2M3nvFOhug%3D%3D 15712218 (Pubitemid 40791769)
59. P Puppo C Introini P Calvi A Naselli 2006 Role of transurethral resection of the prostate and biopsy of the peripheral zone in the same session after repeated negative biopsies in the diagnosis of prostate cancer Eur Urol 49 873 878 10.1016/j.eururo.2005.12.064 10.1016/j.eururo.2005.12.064 16439052
60. M Mitterberger A Pelzer D Colleselli G Bartsch H Strasser L Pallwein, et al. 2007 Contrast-enhanced ultrasound for diagnosis of prostate cancer and kidney lesions Eur J Radiol 64 231 238 10.1016/j.ejrad.2007.07.027 10.1016/j.ejrad.2007.07.027 17881175 (Pubitemid 47588759)
61. L Pallwein M Mitterberger J Gradl F Aigner W Horninger H Strasser, et al. 2007 Value of contrast-enhanced ultrasound and elastography in imaging of prostate cancer Curr Opin Urol 17 39 47 10.1097/MOU.0b013e328011b85c 10.1097/MOU.0b013e328011b85c 17143110 (Pubitemid 44901089)
62. J Tang JC Yang Y Luo J Li Y Li H Shi 2008 Enhancement characteristics of benign and malignant focal peripheral nodules in the peripheral zone of the prostate gland studied using contrast-enhanced transrectal ultrasound Clin Radiol 63 1086 1091 10.1016/j.crad.2007.11.026 10.1016/j.crad.2007.11.026 1:STN:280:DC%2BD1croslOmtA%3D%3D 18774354
63. M Wink F Frauscher D Cosgrove JY Chapelon L Palwein M Mitterberger, et al. 2008 Contrast-enhanced ultrasound and prostate cancer- a multicentre European research coordination project Eur Urol 54 982 992 10.1016/j.eururo. 2008.06.057 10.1016/j.eururo.2008.06.057 18584944
64. BS Garra 2007 Imaging and estimation of tissue elasticity by ultrasound Ultrasound Q 23 255 268 10.1097/ruq.0b013e31815b7ed6 10.1097/ruq. 0b013e31815b7ed6 18090836 (Pubitemid 350307453)
65. ED Nelson CB Slotoroff LG Gomella EJ Halpern 2007 Targeted biopsy of the prostate: the impact of color Doppler imaging and elastography on prostate cancer detection and Gleason score Urology 70 1136 1140 10.1016/j.urology.2007. 07.067 10.1016/j.urology.2007.07.067 18158034 (Pubitemid 350297373)
66. L Pallwein F Aigner R Faschingbauer E Pallwein G Pinggera G Bartsch, et al. 2008 Prostate cancer diagnosis: value of real-time elastography Abdom Imaging 33 729 735 10.1007/s00261-007-9345-7 10.1007/s00261-007-9345-7 18196315
67. G Salomon J Köllerman I Thederan FK Chun L Budäus T Schlomm, et al. 2008 Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy Eur Urol 54 1354 1362 10.1016/j.eururo.2008.02.035 10.1016/j.eururo.2008.02.035 18374470
68. K Kamoi K Okihara A Ochiai O Ukimura Y Mizutani A Kawauchi, et al. 2008 The utility of transrectal real-time elastography in the diagnosis of prostate cancer Ultrasound Med Biol 34 1025 1032 10.1016/j.ultrasmedbio.2007.12.002 10.1016/j.ultrasmedbio.2007.12.002 18255215 (Pubitemid 351893145)
69. KM Pondman JJ Fütterer B ten Haken LJ Schutlze Kool JA Witjes T Hambrock, et al. 2008 MR-guided biopsy of the prostate: an overview of techniques and a systematic review Eur Urol 54 517 527 10.1016/j.eururo.2008.06. 001 10.1016/j.eururo.2008.06.001 18571309
70. K van Renterghem G Van Koeveringe R Achten P Van Kerrebroeck 2007 Clinical relevance of transurethral resection of the prostate in "asymptomatic" patients with an elevated prostate-specific antigen level Eur Urol 52 819 826 10.1016/j.eururo.2007.03.055 10.1016/j.eururo.2007.03. 055 17418482 (Pubitemid 47126164)
71. van Renterghem K, Van Koeveringe G, Achten R, Van Kerrebroeck P (2009) Long-term clinical outcome of a diagnostic transurethral resection of the prostate in patients with an elevated prostate-specific antigen level and minor lower urinary tract symptoms. Urol Int (accepted for publication)
72. K van Renterghem G Van Koeveringe R Achten P van Kerrebroeck 2008 Prospective study of the clinical outcome of a TURP in patients with an elevated prostate specific antigen level, minor lower urinary tract symptoms and proven bladder outlet obstruction Eur Urol 54 1385 1392 10.1016/j.eururo.2008.06.069 10.1016/j.eururo.2008.06.069 18599187
73. JA Eastham MW Kattan P Fearn G Fisher DM Berney T Oliver, et al. 2008 Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group Eur Urol 53 347 354 10.1016/j.eururo.2007.05.015 10.1016/j.eururo.2007.05.015 17544572
74. L Cheng EJ Bergstralh BG Scherer RM Neumann ML Blute H Zincke, et al. 1999 Predictors of cancer progression in T1a prostate adenocarcinoma Cancer 85 1300 1304 10.1002/(SICI)1097-0142(19990315)85:6<1300::AID-CNCR12>3.0.CO;2- # 10.1002/(SICI)1097-0142(19990315)85:6<1300::AID-CNCR12>3.0.CO;2-# 1:STN:280:DyaK1M3gtlSiug%3D%3D 10189135 (Pubitemid 29125083)
75. AR Aro S Pilvikki Absetz TM van Elderen E van der Ploeg LJ van der Kamp 2000 False-positive findings in mammography screening induces short-term distress-breast cancer-specific concern prevails longer Eur J Cancer 26 1089 1097 10.1016/S0959-8049(00)00065-4 10.1016/S0959-8049(00)00065-4 (Pubitemid 30330906)
76. IM Lipkus S Halabi TS Strigo BK Rimer 2000 The impact of abnormal mammograms on psychological outcomes and subsequent screening Psychooncology 9 402 410 10.1002/1099-1611(200009/10)9:5<402::AID-PON475>3.0.CO;2-U 10.1002/1099-1611(200009/10)9:5<402::AID-PON475>3.3.CO;2-L 1:STN:280:DC%2BD3M%2FjtVKhsQ%3D%3D 11038478
77. DA Katz DF Jarrard CA McHorney SL Hillis DA Wiebe DG Fryback 2007 Health perceptions in patients who undergo screening and workup for prostate cancer Urology 69 215 220 10.1016/j.urology.2006.09.059 10.1016/j.urology.2006.09.059 17320653 (Pubitemid 46274922)
78. MK Brawer DW Lin WO Williford K Jones H Lepor 1999 Effect of finasteride and/or terazosin on serum PSA: results of VA cooperative study #359 Prostate 39 234 239 10.1002/(SICI)1097-0045(19990601)39:4<234::AID-PROS3>3.0.CO;2-4 10.1002/(SICI)1097-0045(19990601)39:4<234::AID-PROS3>3.0.CO;2-4 1:CAS:528:DyaK1MXjslyjsLY%3D 10344212 (Pubitemid 29244497)
79. J Pannek LS Marks JD Pearson HG Rittenhouse DW Chan ED Shery, et al. 1998 Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia J Urol 159 449 453 10.1016/S0022-5347(01)63946-6 10.1016/S0022-5347(01)63946-6 1:CAS:528: DyaK1cXmsFOhs78%3D 9649261 (Pubitemid 28049254)
80. SH Sacks SA Aparicio A Bevan DO Oliver EJ Will AM Davison 1989 Late renal failure due to prostatic outflow obstruction: a preventable disease BMJ 298 156 159 10.1136/bmj.298.6667.156 10.1136/bmj.298.6667.156 1:STN:280: DyaL1M7mslWgtw%3D%3D 2466506 (Pubitemid 19039675)
81. AD Rule MM Lieber SJ Jacobsen 2005 Is benign prostatic hyperplasia a risk factor for chronic renal failure? J Urol 173 691 696 10.1097/01.ju.0000153518. 11501.d2 10.1097/01.ju.0000153518.11501.d2 15711245 (Pubitemid 40239321)
82. P Teillac RM Scarpa 2006 Economic issues in the treatment of BPH Eur Urol S5 1018 1024 (Pubitemid 44666588)
83. C Saigal G Joyce 2005 Economic costs of benign prostatic hyperplasia in the private sector J Urol 173 1309 1313 10.1097/01.ju.0000152318.79184.6f 10.1097/01.ju.0000152318.79184.6f 15758787 (Pubitemid 40380559)
84. R Disantostefano A Biddle J Lavelle 2006 An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia BJU Int 97 1007 1016 10.1111/j.1464-410X.2005.06089.x 10.1111/j.1464-410X.2005.06089.x 16542339
85. G Wendt-Nordahl B Bucher A Häcker T Knoll P Alken MS Michel 2007 Improvement in mortality and morbidity in transurethral resection of the prostate over 17 years in a single center J Endourol 21 1081 1087 10.1089/end.2006.0370 10.1089/end.2006.0370 17941791 (Pubitemid 47608933)
86. J Rassweiler D Teber R Kuntz R Hofmann 2006 Complications of transurethral resection of the prostate (TURP)-incidence, management and prevention Eur Urol 50 969 980 10.1016/j.eururo.2005.12.042 10.1016/j.eururo. 2005.12.042 16469429 (Pubitemid 44486473)
87. S Madersbacher J Lackner C Brössner M Röhlich I Stancik M Willinger, et al. 2005 Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long term analysis of 23.123 cases Eur Urol 47 499 504 10.1016/j.eururo.2004.12.010 10.1016/j.eururo.2004.12.010 15774249 (Pubitemid 40357897)
88. O Reich C Gratzke CG Stief 2006 Techniques and long-term results of surgical procedures for BPH Eur Urol 49 970 978 10.1016/j.eururo.2005.12.072 10.1016/j.eururo.2005.12.072 16481092 (Pubitemid 43674012)
89. M Müntener S Aellig R Küttel C Gehrlach D Hauri RT Strebel 2006 Peri-operative morbidity and changes in symptom scores after transurethral prostatectomy in Switzerland: results of an independent assessment of outcome BJU Int 98 381 383 10.1111/j.1464-410X.2006.06256.x 10.1111/j.1464-410X.2006. 06256.x 16879681
90. OW Hakenberg CB Pinnock VR Marshall 2003 Preoperative urodynamic and symptom evaluation of patients undergoing transurethral prostatectomy: analysis of variables for outcome BJU Int 91 375 379 10.1046/j.1464-410X.2003.04078.x 10.1046/j.1464-410X.2003.04078.x 1:STN:280:DC%2BD3s%2FptF2ksw%3D%3D 12603418 (Pubitemid 36359645)
91. P Rodrigues AM Lucon GC Freire S Arap 2001 Urodynamic pressure flow studies can predict the clinical outcome after transurethral prostatic resection J Urol 165 499 502 10.1097/00005392-200102000-00033 10.1097/00005392-200102000- 00033 1:STN:280:DC%2BD3M3jt1WitQ%3D%3D 11176404 (Pubitemid 32060444)
92. Y Tanaka N Masumori N Itoh S Furuya H Ogura T Tsukamoto 2006 Is the short-term outcome of transurethral resection of the prostate affected by preoperative degree of bladder outlet obstruction, status of detrusor contractility or detrusor overactivity? Int J Urol 13 1398 1404 10.1111/j.1442-2042.2006.01589.x 10.1111/j.1442-2042.2006.01589.x 17083391 (Pubitemid 44657047)
93. N Seki M Takei A Yamaguchi S Naito 2006 Analysis of prognostic factors regarding the outcome after transurethral resection for symptomatic benign prostatic enlargement Neurourol Urodyn 25 428 432 10.1002/nau.20262 10.1002/nau.20262 16721841 (Pubitemid 44246636)